Page 108 - CIBERBBN-2015-eng

Research groups
Drug Delivery and Targeting Group
Programme: Nanomedicine
Lead Researcher: Schwartz Navarro, Simó
Group members
STAFF MEMBERS: Fernandes de Sousa Rafael, Diana | Mancilla Zamora, Sandra | Pla Solans, Helena | Santos Benito, Fernando Fidel.
ASSOCIATED MEMBERS: Abasolo Olaortua, Ibane | Alijotas Reig, Jaume | Arango del Corro, Diego | Armengol Carrasco, Manuel | Baldrich Rubio, Eva | Espin Basany, Eloy | Fernández Amurgo, Yolanda | López Cano, Manuel | Sayos Ortega, Juan.
CONTRIBUTORS: Andretta, Elena | Bazzocco, Sarah | García Aranda, Natalia | García Latorre, Laura. Main lines of research
Our group develops research projects mainly fo- cused on oncology and rare diseases.
These projects are conducted around three pre- ferred work areas:
• Área 1: biomarkers and therapeutic targets from suitable experimental models, as molecular bio- markers, diagnostic providers in biosensors (na- nodiagnosis) or for biofunctionalizing new nano- medicines and therapeutic targets for designing new more effective treatments or alternative ther- apeutic strategies (new nanomedicines).
• Área 2: experimental chemistry and applied na- notechnology, especially enhancing the study of polymeric nanomedicines, through simpler chemical synthesis designs and potential scala- bility, as well as new experimental genomic ther-
apies (iRNA, artificial non-viral vectors, etc.) and the study of biomedical applications based on nanotechnology (biosensors) and new biomate- rials.
• Área 3: Validation of targets and functional stud- ies. This is essential for obtaining concept tests and preclinical studies of new biomarkers and targets, as well as of new nanomedicines includ- ing: biodistribution, toxicity, therapeutic activity, specificity, functional molecular studies, etc..., in different in vitro and in vivo experimental models.
Technological Platform on Nanomedicine.
The in vivo experimentation unit allows data to be obtained on the systemic behaviour of biomarkers (biodistribution, pharmacokinetics, pharmacody- namics, toxicity and therapeutic activity) using im-
108 I Annual report 2015 I CIBER-BBN